Clinical Trials Browser

Recurrence × Gemtuzumab × Clear all

NCT04070768 2025-05-04

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Phase 1 Completed

18 enrolled 15 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04050280 2025-05-01

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

Phase 2 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03374332 2024-02-08

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Disease Progression

NCT04173585 2023-03-27

TEAM

Phase 2 Completed

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00660036 2016-01-15

Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Phase 1 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00233909 2008-04-01

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Phase 1/2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Recurrence